Abstract:Ruyu Han, 1, &ast Leijuan Gan, 1, &ast Liyu Sun, 1 Mengran Lang, 2 Xindi Tian, 1 Kangwei Zhu, 1 Lu Chen, 1 Guangtao Li, 1 Tianqiang Song 1 1 Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin, 300060, People's Republic of China; 2 Hepatobiliary Surgery Department, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Tianqiang Song, Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin, 300060, People's Republic of China, Tel +86-22-23340123, Fax +86-22-23537796, Email Purpose: This study aimed to investigate the benefit of conversion therapy for patients with unresectable hepatocellular carcinoma (HCC). Patients and Methods: A retrospective cohort study was conducted involving 40 patients initially deemed unresectable HCC (uHCC). They received surgery following successful conversion therapy involving lenvatinib. The patients were matched in a 1:1 ratio to with a control group who underwent direct surgery, based on pre-treatment clinical data. Results: The median recurrence-free survival (RFS) duration for the conversion therapy cohort was notably longer than that of the direct surgery cohort (25 months vs 11 months). Furthermore, the 1- and 2-year RFS rates were significantly higher in the conversion therapy group compared to the direct surgery group (1 year: 70.5% vs 40.1%; 2 years: 49.0% vs 19.1%). The survival curves indicated a statistically significantly longer RFS in the conversion therapy cohort compared to the direct surgery cohort (P = 0.007). While patients achieving good remission based on both RECIST 1.1 and mRECIST criteria showed superior median RFS, no significant disparity was observed in the survival curves. The subgroup analysis revealed significantly improved prognosis among patients in the conversion therapy group who were male, older, had a history of alcohol consumption, were non-smokers, had liver cirrhosis, possessed Child-Pugh A liver function, had a tumor diameter exceeding 5 cm, and had an AFP ≥ 400 ng/mL. Among the cohort of 40 patients, only 8 individuals encountered severe adverse reactions, which were managed through dose reduction. None of the patients experienced multiple severe adverse reactions concurrently. Conclusion: For patients with unresectable hepatocellular carcinoma, conversion therapy offers a significantly better prognosis than direct surgery for uHCC patients. Keywords: hepatocellular carcinoma, conversion therapy, recurrence-free survival, hepatic resection Hepatocellular carcinoma (HCC) presents a formidable challenge to public health, characterized by high incidence and mortality rates compared to other malignancies. 1 The primary radical interventions for HCC encompass hepatic resection (HR), liver transplantation (LT), and radiofrequency ablation (RFA). 2 These modalities exclusively recommended for patients in the early stages. 3 Unfortunately, the majority of HCC cases are diagnosed at intermediate to advanced stages, precluding the feasibility of surgical interventions. 4,5 Historically, therapeutic options for these patients were constrained due to the absence of effective pharmaceutical interventions. 6 However, the advent of targeted therapies and immunotherapies has substantially broadened the therapeutic armamentarium for HCC, yielding increasingly efficacious treatments. 7–9 Consequently, the landscape of therapeutic options for patients with intermediate and advanced HCC has progressively expanded. In recent years, conversion therapy has emerged as a key component in the diagnostic and therapeutic strategy for intermediate and advanced HCC. 10,11 Conversion therapy aims to offer localized or systemic treatment to patients initially deemed unresectable, potentially enabling them to undergo radical treatment. 5 Such patients can be categorized into two distinct groups. One category comprises those who are unresectable due to -Abstract Truncated-

Clinical study on conversion therapy of hepatocellular carcinoma - summary and comparison of clinical data from a single center of consecutive four years

[Advancements and Controversies in Conversion Therapy for Biliary Tract Malignant Tumors with Insufficient Future Liver Remnant].

Comparison of survival benefit and safety between surgery following conversion therapy versus surgery alone in patients with surgically resectable hepatocellular carcinoma at CNLC IIb/IIIa stage: a propensity score matching study

Pathological complete response after conversion therapy in unresectable hepatocellular carcinoma: a retrospective study

Real-world practice of conversion surgery for unresectable hepatocellular carcinoma - a single center data of 26 consecutive patients

Conversion Therapy of Hepatocellular Carcinoma: Some Pivotal Issues to Be Resolved

Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis

Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study

Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)

Conversion Therapy for Massive Hepatocellular Carcinoma: A Case Report and Literature Review

Comparison of survival benefit between salvage surgery after conversion therapy versus surgery alone for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis

Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities

Benefit of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score-Matched Study

Successful conversion therapy for unresectable hepatocellular carcinoma is getting closer: A systematic review and meta-analysis

Conversion therapy in liver transplantation for hepatocellular carcinoma: What's new in the era of molecular and immune therapy?

Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study

Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study.

Efficacy and safety of tislelizumab combined with lenvatinib and FOLFOX4-HAIC in conversion therapy of middle-advanced stage hepatocellular carcinoma (HCC): A real-world retrospective study.

Conversion therapy for unresectable hepatocellular carcinoma: Advances and challenges

Conversion Therapy of Intrahepatic Cholangiocarcinoma is Associated with Improved Prognosis and Verified by a Case of Patient-Derived Organoid

Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis